{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Multiple+Myeloma+Research+Consortium",
    "query": {
      "sponsor": "Multiple Myeloma Research Consortium"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Multiple+Myeloma+Research+Consortium&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T23:32:20.836Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01497093",
      "title": "Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2012-02-15",
      "completion_date": "2019-07-23",
      "has_results": false,
      "last_update_posted_date": "2020-04-07",
      "last_synced_at": "2026-10-03T23:32:20.836Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01497093"
    },
    {
      "nct_id": "NCT03732703",
      "title": "Myeloma-Developing Regimens Using Genomics (MyDRUG)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Abemaciclib, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Enasidenib, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Erdafitinib, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Selinexor, dexamethasone, ixazomib, pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Multiple Myeloma Research Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2019-04-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-10-03T23:32:20.836Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03732703"
    },
    {
      "nct_id": "NCT01183949",
      "title": "Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "AT7519M",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2010-11",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-10-03T23:32:20.836Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183949"
    },
    {
      "nct_id": "NCT01562405",
      "title": "Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "ACE-011",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2012-05",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-10-03T23:32:20.836Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01562405"
    },
    {
      "nct_id": "NCT02253316",
      "title": "Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Ixazomib",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 236,
      "start_date": "2015-01-20",
      "completion_date": "2026-08-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-03T23:32:20.836Z",
      "location_count": 10,
      "location_summary": "Duarte, California • San Francisco, California • Denver, Colorado + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02253316"
    },
    {
      "nct_id": "NCT06171685",
      "title": "MMRC Horizon One: RRMM (MMRC-099)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapse Multiple Myeloma",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Teclistamab Monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Teclistamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Multiple Myeloma Research Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 300,
      "start_date": "2024-11-17",
      "completion_date": "2030-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-10-03T23:32:20.836Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06171685"
    },
    {
      "nct_id": "NCT05560399",
      "title": "A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Iberdomide",
          "type": "DRUG"
        },
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2023-02-06",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-10-03T23:32:20.836Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05560399"
    },
    {
      "nct_id": "NCT02718833",
      "title": "A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2016-06-21",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-03T23:32:20.836Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Danvers",
          "state": "Massachusetts"
        },
        {
          "city": "Newton",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02718833"
    },
    {
      "nct_id": "NCT03236428",
      "title": "Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Monoclonal Gammopathy",
        "Smoldering Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2017-11-24",
      "completion_date": "2026-10-04",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-03T23:32:20.836Z",
      "location_count": 6,
      "location_summary": "Monterey, California • Denver, Colorado • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03236428"
    },
    {
      "nct_id": "NCT07053436",
      "title": "Horizon Two: HR NDMM (MMRC-100)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Risk Newly Diagnosed Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Bispecific Monoclonal Antibody and Triplet Therapy",
          "type": "DRUG"
        },
        {
          "name": "Monoclonal Antibody with Stem Cell Transplant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Multiple Myeloma Research Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2026-04-30",
      "completion_date": "2035-10-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-03T23:32:20.836Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053436"
    }
  ]
}